The ministry of health and family welfare has prohibited the manufacture for sale, sale or distribution for human use of 328 fixed dose combinations (FDCs) with immediate effect. It has also restricted the manufacture, sale or distribution of six FDCs subject to certain conditions.
Earlier, the Central government had, through its notifications published on the 10th March, 2016 in the Gazette of India, prohibited the manufacture for sale, sale and distribution for human use of 344 FDCs under section 26 A of the Drugs and Cosmetics Act, 1940. Subsequently, the Government had prohibited five more FDCs in addition to the 344 under the same provisions.
However, the matter was contested by the affected manufacturers in various High Courts and the Supreme Court of India. In compliance with the directions given by the Supreme Court of India in its judgment dated the 15th December, 2017, the matter was examined by the Drugs Technical Advisory Board constituted under section 5 of the Drugs and Cosmetics Act, 1940 which furnished its report on these drugs to the Central Government.
The Drugs Technical Advisory Board recommended, amongst other things, that there is no therapeutic justification for the ingredients contained in 328 FDCs and that these FDCs may involve risk to human beings. The Board recommended that it is necessary to prohibit the manufacture, sale or distribution of these FDCs under section 26 A of the Drugs and Cosmetics Act, 1940 in the larger public interest. With regard to six FDCs, the Board recommended that their manufacture, sale and distribution be restricted subject to certain conditions based on their therapeutic justification. Fifteen FDCs out of the 344 prohibited on the 10th March, 2016, which were claimed to be manufactured prior to 21st September, 1988, have been kept out of the purview of current notifications.
Earlier, an Expert Committee appointed by the Central Government had also examined these FDCs and made recommendations in line with those of the Board as indicated above.
The Central Government considered the recommendations of the Expert Committee and Drugs Technical Advisory Board, and based on such consideration, it was concluded that it is necessary and expedient in public interest to prohibit the manufacture for sale, sale and distribution for human use of these 328 FDCs in the country.
Accordingly, the ministry of health and family welfare has, in exercise of powers conferred by section 26A of the Drugs and Cosmetics Act, 1940, prohibited the manufacture for sale, sale or distribution for human use of 328 FDCs through its gazette notifications dated 7th September 2018; it has also restricted the manufacture, sale or distribution of six FDCs subject to certain conditions. These notifications will take immediate effect.
more recommended stories
Raid at Natural Health Clinic; Dr. Farrah Forced to Flee
PHILIPPINES: Dr. Farrah Agustin-Bunch of the.
NACO Report: India has 21.40 Lakh People Living with HIV-AIDS
NEW DELHI: India has approximately 21.40.
Global Health Regulators Find Second Toxin in Common Heart Drug
FRANKFURT/BENGALURU: European and North American regulators.
Karnataka Government Cuts Fuel Prices by Rs 2 Per Litre
BANGALORE: In the wake of record-breaking.
Cop Suspended for Sending Accident Victims to Private Hospitals in Haryana
CHANDIGARH: A police officer has been.
ILLEGIBLE : Allahabad HC Summons Doctor to Explain Scribbled Diagnosis in Person
LUCKNOW: In a no longer so.
More than 18 Million New Cases of Cancer Expected this Year: UN
UNITED NATIONS: More than 18 million.
Rising Global Temperatures Likely to Up Heat-related Deaths
LONDON: Countries need to keep global.
Shun Nepotism, Consult me on Foreign Trips: PM Modi tells BJP Chief Ministers
NEW DELHI: Prime Minister Narendra Modi.
Formulate Rules to Regulate Clinical Drug Trials on Humans: Supreme Court
NEW DELHI: The Supreme Court Wednesday.